Acacia Research has announced a settlement in its patent infringement suit against AstraZeneca. The suit, Accuhale vs. AstraZeneca, was filed in December 2011, shortly after Acacia announced that it had acquired patents for inhaler technology from “a major medical company.” No terms were disclosed. The suit claimed that AstraZeneca's Symbicort pMDI infringed on US … [Read more...] about Settlement in Accuhale suit against AstraZeneca
Business
Savara gets $1.7 million for AeroVanc development
Cystic Fibrosis Foundation Therapeutics (CFFT) has awarded Savara Pharmaceuticals $1.7 million for further development of AeroVanc inhaled vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis patients. CFFT is a nonprofit affiliate of the Cystic Fibrosis Foundation that supports discovery and development … [Read more...] about Savara gets $1.7 million for AeroVanc development
Insmed provides update on Arikace for NTM
Insmed has announced that it anticipates discussions with the EMA by the end of 2013 regarding Arikace inhaled liposomal amikacin for the treatment of nontuberculous mycobacterial (NTM) lung disease and that it has already initiated the Scientific Advice Working Party (SAWP) process. The company says that it is also looking to take advantage of a "globally … [Read more...] about Insmed provides update on Arikace for NTM
Dance Biopharm to partner with Harmony Asset for inhaled insulin
Under a new joint venture, Harmony Asset will pay development costs for Dance Biopharm's Adagio inhaled insulin in Asian countries, including Korea, India, Indonesia and Australia, Dance has announced. The agreement excludes Japan. Harmony will have majority ownership of the joint venture, and the board of directors will be comprised of an equal number of … [Read more...] about Dance Biopharm to partner with Harmony Asset for inhaled insulin
Nephron recalls albuterol inhalation solution
Nephron Pharmaceuticals has announced a voluntary recall of ten lots of albuterol inhalation solution "as a precautionary measure, due to results from . . . internal monitoring processes." The company says that it has not received reports of reportable adverse events for the 0.083% solution and that the lots met Nephron's quality specifications when … [Read more...] about Nephron recalls albuterol inhalation solution
FDA approves non-prescription Nasacort Allergy 24HR nasal spray
Sanofi has announced today that its Nasacort Allergy 24HR triamcinolone acetonide nasal spray for the treatment of nasal allergies will be available over-the-counter beginning in spring 2014 now that the FDA has approved it as an OTC product. Sanofi's consumer healthcare division, Chattem, Inc. will market the product. An FDA advisory committee recommended approval … [Read more...] about FDA approves non-prescription Nasacort Allergy 24HR nasal spray
Teva announces plans for expanded respiratory business
During a recent web presentation on its respiratory R&D activities, Teva announced that it plans to make 13 regulatory submissions for respiratory products over the next 5 years, introduce "proprietary devices addressing unmet needs," and expand its respiratory business to become "a multi-billion $ franchise by the end of the decade." According to the company, its … [Read more...] about Teva announces plans for expanded respiratory business
Cirrus gets FDA grant for MDI formulation study
The US FDA has awarded a grant to Cirrus Pharmaceuticals for a study titled “Comprehensive Evaluation of Formulation Effects on Metered Dose Inhaler Performance,” the company has announced. According to Cirrus, the study will "investigate the effects of excipient concentrations and API particle size on the aerosolization performance of metered dose inhaler (MDI) … [Read more...] about Cirrus gets FDA grant for MDI formulation study
Hovione announces successful FDA inspection
Inhalation particle design and manufacturing specialist Hovione has announced the completion of an FDA GMP and postmarket approval inspection of its manufacturing plant in Loures, Portugal. According to the company, no Form 483 was issued after the 5-day inspection, which was completed on September 27, 2013, and the inspector "informed that she was satisfied with what … [Read more...] about Hovione announces successful FDA inspection
Mystic gets additional patents for intranasal technology
Mystic Pharmaceuticals has announced that it has received a notice of allowance from the China Patent Office for a patent application titled “Deep Draw Container Forming Method” (invention number ZL200880106965.1). The company also said that it received a notice of allowance for an application titled “Combination Unit Dose Dispensing Container” (application number … [Read more...] about Mystic gets additional patents for intranasal technology